Lathosterol and other Noncholesterol Sterols in Treatment of Hereditary Hypercholesterolemias: 20-Year Experience among School Children and Adolescents
DOI:
https://doi.org/10.6000/1929-5634.2018.07.02.2Keywords:
Noncholesterol sterols, lathosterol, desmosterol, campesterol, sitosterol, phytosterols, heterozygous familial hypercholesterolemia, alimentary hyperlipidemia, monitoring diet and drug treatment, simvastatins, ezetimibe.Abstract
Aims: This paper presents our 20-year experience with diagnosing heterozygous familial hypercholesterolemia (HFH) and monitoring its diet and drug treatment in 94 children (6-18 years) by means of noncholesterol sterols (NCS), namely lathosterol (Lat) and desmosterol (Des) as cholesterol synthesis precursors, and campesterol (Cam) and sitosterol (Sit) as cholesterol absorption precursors.
Patients and Methods: Four groups were included in the study: (1) 64 children with genetically confirmed HFH; (2) 30 children with clinical and laboratory symptoms of HFH where the relevant genetic mutations have not been found; (3) 77 children with alimentary hyperlipidemia (AH), and (4) 84 healthy children as a control group. The followed-up markers were routine lipid profile comprising total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triacylglycerides (TAG), complemented by apolipoprotein A1 (ApoA), apolipoprotein B (ApoB), lipoprotein(a) (Lp(a)), low-density lipoprotein receptor (LDL-R), apolipoprotein E (ApoE) polymorphism, and plasma NCS (Lat, Des, Cam and Sit), the latter being established by means of GC/MS. The medical treatment of HFH patients consisted of simvastatin and ezetimibe. Correlations between TC lowering and decrease in Lat and other NCS values during combination treatment were examined in various types of hypercholesterolemia.
Results: HFH patients, whether genetically confirmed or not, exhibit a significant decrease in Lat (and in milder concentrations also Des) which correlates directly to the TC lowering during the combination therapy (r = 0.912 for Lat;
r = 0.798 for Des; p<0.001). Cam and Sit do not correlate with the TC lowering at all (r = -0.378 for Cam; r = -0.208 for Sit). By contrast, high TC levels in AH patients are not accompanied by significantly elevated Lat levels, and, therefore, caloric restriction cannot result in significant Lat or Des decrease (p<0.001). Lat and Des levels are also high following drug treatment interruption during long vacations or when the drug treatment is neglected. Compensatory elevation of Cam and Sit occurs in 50% of treated children patients after the desirable TC level below 4.8 mmol/l has been achieved and maintained. In our experience, the combination of statin and ezetimibe is the most efficacious therapy to lower TC together with Lat and Des in children with HFH.
Conclusions: Inclusion precursors for cholesterol synthesis and absorption in laboratory testing improve differential diagnosis of HFH, and makes monitoring and/or treatment of pediatric patients more precise and convenient.
References
Avis HJ, Hutten BA, Gagné V, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010; 55: 1121-26. https://doi.org/10.1016/j.jacc.2009.10.042 DOI: https://doi.org/10.1016/j.jacc.2009.10.042
Wiegman A, Hutten BA, deGroot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004; 292: 331-337. https://doi.org/10.1001/jama.292.3.331
deJongh S, Ose L, Szamosi T, Gagne C, Lambert M, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo controlled trial with simvastatin. Circulation 2002; 106: 2231-37. https://doi.org/10.1161/01.CIR.0000035247.42888.82 DOI: https://doi.org/10.1161/01.CIR.0000035247.42888.82
Gauer R. Hyperlipidemia treatment in children:The younger, the better. Am Family Physician 2010; 82: 462-477.
Bogsrud MP, Langslet G, Wium C, et al. Treatment goal attainment in children with familial hypercholesterolemia:a cohort study of 302 children in Norway. J Clin Lipidol 2017. DOI: https://doi.org/10.1016/j.jacl.2017.11.009
https://doi.org.10.1016/j.jact2017.11.009
Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. Pediatrics, 2011, S 213-S256. DOI: https://doi.org/10.1542/peds.2009-2107C
Noto D, Cefalu ABC, Barraco G, et al. Plasma non-cholesterol sterols: a useful diagnostic tool in pediatric hypercholesterolemia. Pediatr Res 2010; 67: 200-204. https://doi.org/10.1203/PDR.0b013e3181c8f035 DOI: https://doi.org/10.1203/PDR.0b013e3181c8f035
Hedman M, Miettinen TA, Gylling H, Ketomäki A, Antikainen M. Serum noncholesterol sterols in children with hetero-zygous familial hypercholesterolemia undergoing pravastatin therapy. J Pediat 2006; 148: 241-246. https://doi.org/10.1016/j.jpeds.2005.08.068 DOI: https://doi.org/10.1016/j.jpeds.2005.08.068
Nissien MJ, Miettinen TE, Gylling H, Miettinen TA. Applicability of noncholesterol sterols in predicting response in cholesterol metabolism to simvastatin and fluvastatin treatment among hypercholesterolemic men. Nutr Metab Cardiovasc Dis 2010; 20: 308-316. https://doi.org/10.1016/j.numecd.2009.04.014 DOI: https://doi.org/10.1016/j.numecd.2009.04.014
Rodenburg J, Wissers MN, Wiegmasn A, et al. Statin treatmen tin children with familial hypercholesterolemia: a ranadomized controlled trial. JAMA 2004; 292: 331-37. https://doi.org/10.1001/jama.292.3.331 DOI: https://doi.org/10.1001/jama.292.3.331
McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a specific statement from the American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007; 115: 1948-67. https://doi.org/10.1161/CIRCULATIONAHA.107.181946 DOI: https://doi.org/10.1161/CIRCULATIONAHA.107.181946
Hyanek J, Martinikova V, Matoska V, et al. 10years experience with medical treatment of familial hypercholesterolemia in children and adolescents. Česko-slov. pediatrie 2006; 61: 404-412, (in Czech with English summary).
NCEP Expert panel of blood cholesterol levels in children and adolescents.National Cholesterol Education Program(NCEP):Highlights of the Report of the Expert Panel on Pediatrics 1992; 89: 495-501. DOI: https://doi.org/10.1542/peds.89.3.495
Rifkind BM, Segal P. Lipid research clinic program reference values for hyperlipidemia and hypolipidemia. JAMA 1983; 250: 1869-1872. https://doi.org/10.1001/jama.1983.03340140039025 DOI: https://doi.org/10.1001/jama.250.14.1869
Clauss S, Wai KM, Kavey RW, Kuehl K. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediat 2009; 154: 869-872. https://doi.org/10.1016/j.jpeds.2008.12.044 DOI: https://doi.org/10.1016/j.jpeds.2008.12.044
Hyanek J, Pehal F, Dubska L, et al. Lathosterol and noncholesterol sterols in routine use for the differentiation andmonitoring of dietary and drug induced treatment of hypercholesterolemias in children and adolescents. JNT 2014; 3: 1-12. DOI: https://doi.org/10.6000/1929-5634.2014.03.01.1
Hyanek J. Serum non-cholesterol sterols in differentiation and treatment of children suffering from hypercholesterolemias; Chapter VI. In Phytosterols-Food Sources, Functions and Health Benefits (Ed. D. Garner), Progress in Food Science and Technology. NOVA´s website 2015; pp. 97-116.
Francova H, Trbusek M, Zapletalova P, et al. New promoter mutations in the low-density lipoprotein receptor gene which induced familialhypercholesterolemia phenotype. Molecular and functional analysis. J Inher Metab Dis 2004; 27: 523-28. https://doi.org/10.1023/B:BOLI.0000037337.93335.c4 DOI: https://doi.org/10.1023/B:BOLI.0000037337.93335.c4
Tichy L, Fajkusova L, Zapletalova P, et al. Molecular genetic backgraund on an autosomal dominant hypoercholessterolemia in the Czech Republic Physiol Res 2017; 66(Suppl.1): S47-54. DOI: https://doi.org/10.33549/physiolres.933587
Tichy L, Freiberg T, Zapletalov P, et al. The molecular basis offamilial cholesterolemia in Czech Republic: spetrum of LDLR mutations and genotype-phenotype corrrelations. Atherosclerosis 2012; 223: 401-8. https://doi.org/10.1016/j.atherosclerosis.2012.05.014 DOI: https://doi.org/10.1016/j.atherosclerosis.2012.05.014
Phillips KM, Ruggio DM, Bailey JA. Precise quantitative determination of phytosterols, stenols, and cholesterol metabolites in human serum, by capillary gas-liquid chromatography. J Chromatog 1999; B732: 17-29. DOI: https://doi.org/10.1016/S0378-4347(99)00257-1
Theunissen CE, Regente J, Bergman K, et al. Serum cholesterol precursors and metabolites and cognitive performace in an aging population. Neurobiol Aging 2003; 24: 147-155. https://doi.org/10.1016/S0197-4580(02)00061-1 DOI: https://doi.org/10.1016/S0197-4580(02)00061-1
Hyanek J, Dubska L, Martinikova V, et al. The influence of menarche on high cholesterol level in adolescent girls with familial hypercholesterolemia. Čs Slov Pediat 2013; 68: 12-18. (in Czech with English summary).
MacKay DS, Jones PJH. Plasma noncholesterol sterols:corrent uses potential and need for standardization. Curr Opin Lipidol 2012; 23: 241-47. https://doi.org/10.1097/MOL.0b013e328353292e DOI: https://doi.org/10.1097/MOL.0b013e328353292e
MacKay DS, Jones PJH. Evaluation of methods for the determination of cholesterol absorption and synthesis in humans. Atherosclerosis 2001; 218: 253-62. https://doi.org/10.1016/j.atherosclerosis.2010.04.022 DOI: https://doi.org/10.1016/j.atherosclerosis.2010.04.022
Sutherland WHF, Williamns MJA, Nye NJ, Restieaux NJ, deJong SA, Walker HL. Associations of plasma noncholesterol sterol levels with severity of coronary artery disease. Nutr Metab Cardiovasc Dis 1998; 8: 389-391.
Sudhop T, Reber M, Tribble D, et al. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J Lipid Res 2009; 50: 2117-2123. https://doi.org/10.1194/jlr.P900004-JLR200 DOI: https://doi.org/10.1194/jlr.P900004-JLR200
Lupatelli G, Pirro M, Siepi D, et al. Non-cholesterol sterols in different forms of primary hyperlipemias. Nutr Metab Cardiovasc Dis 2012; 22: 231-6. https://doi.org/10.1016/j.numecd.2010.05.010 DOI: https://doi.org/10.1016/j.numecd.2010.05.010
Miettinen TA, Gylling H, Nissinen MJ. The role of serum non-cholesterol sterols as surrogate markers of absolute cholesterol synthesis and absorption. Nutr Metab Cardiovasc Dis 2011; 21: 765-769. https://doi.org/10.1016/j.numecd.2011.05.005 DOI: https://doi.org/10.1016/j.numecd.2011.05.005
Downloads
Published
How to Cite
Issue
Section
License
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
